Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
filing form 14C increasing AS to 1 billion from 150 million!
http://archive.fast-edgar.com/20201015/AJ2TE22CLW22AJ22222H2ZY2CU6DZ222E222/
0.0460 lol BOUNCING UP NOW
looks like major bounce coming your way longs!
Any 8-K MUST come out from the SEC website FIRST! Can not be posted anywhere before SEC approve it period!! who's taking the chance of holding overnight!!!!
where all these people coming out from at the same time LMAO
coming down now! hope you guys sold the top! profit takers
Jerry are you okay with your fill? looks like it tanks right after you got these 0.0012!!
no, perhaps it went to INNO! seems they are going back to HALB again!
Exactly! top OTC mover now!
monster mover just can't stop!
Huge buying going through
loaded on yesterday's dip, going to bounce back to 0.02 soon!
WOW ask getting real thin! jumping fast! ASCM keeps bidding
HALB 0.0225 NHOD WOWZRS! HUGE Antibody Against Covid-19 NEWS:
Arizona State University/Halberd Develop Antibody Against Covid-19
Press Release | 10/13/2020
JACKSON CENTER, PA / ACCESSWIRE / October 13, 2020 / Halberd Corporation (OTC PINK:HALB) reported that Arizona State University researchers, utilizing the intellectual property of Halberd Corporation, have successfully generated an anti-Spike protein monoclonal antibody against Covid-19. The Spike Protein is a main component of the Covid-19 virus, and is a crucial component in its ability to replicate. In addition, the researchers have sent for synthesis, genes for the creation of new, unique monoclonal antibodies against the SARS-CoV-2 Spike Protein. The performance has exceeded expectations, and Halberd and ASU intend to file for joint patent protection.
Development continues toward three major potential utilizations of the antibody against the Coronavirus:
A Preventative;
A Diagnostic, and
A Therapeutic Treatment.
William A. Hartman, Halberd Corporation Chairman, President & CEO, stated, "We are very excited about our progress to date and plan to issue regular progress reports to keep the public aware of our significant developments."
The details of the Halberd-ASU research contract can be viewed here.
For more information please contact:
William A. Hartman
w.hartman@halberdcorporation.com
support@halberdcorporation.com
www.halberdcorporation.com
P. O. Box 25
Jackson Center, PA 16133
Twitter: @HalberdC
About Arizona State University.
Arizona State University is a public research university with 5 campuses in and around Phoenix, with four regional centers throughout Arizona. It is one of the largest public universities, based on enrollment, and one of the fastest growing research universities in the United States. The school boasts over 400 National Academies-honored faculty, and 77 elite programs.
About Halberd Corporation.
Halberd Corporation. (OTC PINK:HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. Halberd's Articles of Incorporation prohibit the company from issuance of convertible debt which would result in dilution. See the company's Articles of Incorporation here. The number of outstanding shares remains at 317,721,539.
The company holds the exclusive rights to the COVID-19 extracorporeal treatment technology provisional patent applications: "Method for Treating and Curing Covid-19 Infection;" "Method for Treating COVID-19 Inflammatory Cytokine Storm for the Reduction of Morbidity and Mortality in COVID-19 Patients;" "Method for Treating and Curing COVID-19 Infection by Utilizing a Laser to Eradicate the Virus", and, "Nasal Spray To Prevent The Transmission Of Covid-19 Between Humans." Halberd also holds the exclusive rights to the underlying granted U.S. Patent 9,216,386 and U.S. Patent 8,758,287.
Safe Harbor Notice
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). The Companies caution that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. The Companies undertake no obligation to revise these statements following the date of this news release.
Investor caution/added risk for investors in companies claiming involvement in COVID-19 initiatives -
On April 8, 2020, SEC Chairman Jay Clayton and William Hinman, the Director of the Division of Corporation Finance, issued a joint public statement on the importance of disclosure during the COVID-19 crisis.
The SEC and Self-Regulatory Organizations are targeting public companies that claim to have products, treatment or other strategies with regard to COVID-19.
The ultimate impact of the COVID-19 pandemic on the Company's operations is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak. Additionally, new information may emerge concerning the severity of the COVID-19 pandemic, and any additional preventative and protective actions that governments, or the Company, may direct, which may result in an extended period of continued business disruption, reduced customer traffic and reduced operations. Any resulting financial impact cannot be reasonably estimated at this time.
We further caution investors that our primary focus and goal is to battle this pandemic for the good of the world. As such, it is possible that we may find it necessary to make disclosures which are consistent with that goal, but which may be adverse to the pecuniary interests of the Company and of its shareholders.
SOURCE: Halberd Corporation
View source version on accesswire.com:
https://www.accesswire.com/610237/Arizona-State-UniversityHalberd-Develop-Antibody-Against-Covid-19
bounce time!
Long day to go! lots of room! happy for you longs! this news can push PPS for days!0.05 to 0.10 range!!
HALB 0.0210 that is massive news! monoclonal antibody against Covid-19.
https://www.otcmarkets.com/stock/HALB/news/Arizona-State-UniversityHalberd-Develop-Antibody-Against-Covid-19?id=276725
EASY 0.10 upcoming days!!!
real news .. it is posted on OTC DISCLOSURE & NEWS SERVICE which only the Company can post on!
https://www.otcmarkets.com/stock/HALB/news
HALB you got to admit! HUGE Antibody Against Covid-19 NEWS!0.02/0.03 possible Today! Good luck longs
Arizona State University/Halberd Develop Antibody Against Covid-19
Press Release | 10/13/2020
JACKSON CENTER, PA / ACCESSWIRE / October 13, 2020 / Halberd Corporation (OTC PINK:HALB) reported that Arizona State University researchers, utilizing the intellectual property of Halberd Corporation, have successfully generated an anti-Spike protein monoclonal antibody against Covid-19. The Spike Protein is a main component of the Covid-19 virus, and is a crucial component in its ability to replicate. In addition, the researchers have sent for synthesis, genes for the creation of new, unique monoclonal antibodies against the SARS-CoV-2 Spike Protein. The performance has exceeded expectations, and Halberd and ASU intend to file for joint patent protection.
Development continues toward three major potential utilizations of the antibody against the Coronavirus:
A Preventative;
A Diagnostic, and
A Therapeutic Treatment.
William A. Hartman, Halberd Corporation Chairman, President & CEO, stated, "We are very excited about our progress to date and plan to issue regular progress reports to keep the public aware of our significant developments."
The details of the Halberd-ASU research contract can be viewed here.
https://www.otcmarkets.com/stock/HALB/news/Arizona-State-UniversityHalberd-Develop-Antibody-Against-Covid-19?id=276725
I think it is! this will go for days! good for longs.
HALB Develop Antibody Against Covid-19! isn't that huge news for HALB?
Arizona State University/Halberd Develop Antibody Against Covid-19
Press Release | 10/13/2020
JACKSON CENTER, PA / ACCESSWIRE / October 13, 2020 / Halberd Corporation (OTC PINK:HALB) reported that Arizona State University researchers, utilizing the intellectual property of Halberd Corporation, have successfully generated an anti-Spike protein monoclonal antibody against Covid-19. The Spike Protein is a main component of the Covid-19 virus, and is a crucial component in its ability to replicate. In addition, the researchers have sent for synthesis, genes for the creation of new, unique monoclonal antibodies against the SARS-CoV-2 Spike Protein. The performance has exceeded expectations, and Halberd and ASU intend to file for joint patent protection.
Development continues toward three major potential utilizations of the antibody against the Coronavirus:
A Preventative;
A Diagnostic, and
A Therapeutic Treatment.
William A. Hartman, Halberd Corporation Chairman, President & CEO, stated, "We are very excited about our progress to date and plan to issue regular progress reports to keep the public aware of our significant developments."
The details of the Halberd-ASU research contract can be viewed here.
For more information please contact:
William A. Hartman
w.hartman@halberdcorporation.com
support@halberdcorporation.com
www.halberdcorporation.com
P. O. Box 25
Jackson Center, PA 16133
Twitter: @HalberdC
About Arizona State University.
HALB Develop Antibody Against Covid-19! isn't that huge news for HALB?
Arizona State University/Halberd Develop Antibody Against Covid-19
Press Release | 10/13/2020
JACKSON CENTER, PA / ACCESSWIRE / October 13, 2020 / Halberd Corporation (OTC PINK:HALB) reported that Arizona State University researchers, utilizing the intellectual property of Halberd Corporation, have successfully generated an anti-Spike protein monoclonal antibody against Covid-19. The Spike Protein is a main component of the Covid-19 virus, and is a crucial component in its ability to replicate. In addition, the researchers have sent for synthesis, genes for the creation of new, unique monoclonal antibodies against the SARS-CoV-2 Spike Protein. The performance has exceeded expectations, and Halberd and ASU intend to file for joint patent protection.
Development continues toward three major potential utilizations of the antibody against the Coronavirus:
A Preventative;
A Diagnostic, and
A Therapeutic Treatment.
William A. Hartman, Halberd Corporation Chairman, President & CEO, stated, "We are very excited about our progress to date and plan to issue regular progress reports to keep the public aware of our significant developments."
The details of the Halberd-ASU research contract can be viewed here.
For more information please contact:
William A. Hartman
w.hartman@halberdcorporation.com
support@halberdcorporation.com
www.halberdcorporation.com
P. O. Box 25
Jackson Center, PA 16133
Twitter: @HalberdC
About Arizona State University.
HALB massive COVID-19 news! Arizona State University/Halberd Develop Antibody Against Covid-19
https://www.otcmarkets.com/stock/HALB/news/Arizona-State-UniversityHalberd-Develop-Antibody-Against-Covid-19?id=276725
okay! whatever...
nothing new! last update was 11/2019!!
https://who.is/whois/inspyrtherapeutics.com
http://www.inspyrtx.com/ isn't active and still! but http://inspyrtherapeutics.com is been active for awhile!
old news, it has been on for awhile lol
https://who.is/whois/inspyrtherapeutics.com
round 2 on a slow day! watch it here!
dumping about to occur here again! 3 known pumpers ready to exit all!
GL! will leave it here.
most of the 15+ million liabilities are convertible CD
nice move but remember..Total current liabilities $15,453,627 https://www.otcmarkets.com/filing/html?id=14344006&guid=GwkeUn_AwxCuSth
and current direct public Offering price per share will be $0.00374 http://archive.fast-edgar.com/20201007/AKZZ662CZ22FSZTN222B2ZZ2SBPDZZ28Z922/
as expected! down 20% hope new bagholders have learned something! trust your own dd!
WiseTrader Sunday, 10/11/20 11:40:54 AM
Re: None 0
Post #
31395
of 31610
I see a ridiculous price targets made by already "in" traders whose will exit on the morning "gap & drop" open!
price 0.05/0.10 as high as $3.00 projection? all failed! lol where are they these people? they all left the building!? $10 million in liabilities isn't easy!
I see a ridiculous price targets made by already "in" traders whose will exit on the morning "gap & drop" open!
What happed with previous merger Lewis and Clark Pharmaceuticals!! and the $100 million unsecured loan with Milost Global!! There's $10 million liabilities ready to be dumped! Trials all suspended! Read older news all 8-Ks! Do some real DD before buying into dilution spree!
$4,000 cash and over $10,000.000 in liability and you still think this will go 0.25!!!
https://www.otcmarkets.com/filing/html?id=14336185&guid=O0n6Ue8-4JTWGyh
From Twitter $NSPX
Why would anyone Pump $$ into a co. w/ nothing but Patents, Suspended Trials, shareholder dilution and 4 reverse splits?!? Supposed Reaquisition of their delivery system tech is just PR Fluff w/o proof & pointless w/o trials. Notice the Trials aren't even on their website!
$NSPX Why would anyone Pump $$ into a co. w/ nothing but Patents, Suspended Trials, shareholder dilution and 4 reverse splits?!? Supposed Reaquisition of their delivery system tech is just PR Fluff w/o proof & pointless w/o trials. Notice the Trials aren't even on their website! pic.twitter.com/0x0zY2iBe0
— Mimi (@KMichelleMosley) October 10, 2020
HTDOG said it is a good news? i think it's not! Termination Agreement [color=red][/color]whereby the parties terminated the licensing agreement previously entered into on August 3, 2018 https://www.otcmarkets.com/filing/html?id=14435377&guid=E7p6Unp_fO1d-3h
why would Ridgeway Therapeutics, Inc terminated the licensing agreement after so many years? if it is useful and profitable, why Company has only 4K cash and huge 5 million in debt??'
(in thousands, except share and per share data)
June 30, December 31,
2020 2019
(Unaudited)
ASSETS
Current assets:
Cash $ 4 $ 4
Restricted cash 112 19
Total current assets 116 23
Total assets $ 116 $ 23
LIABILITIES AND STOCKHOLDERS’ DEFICIT
Current liabilities:
Accounts payable $ 2,283 $ 2,269
Accrued expenses 1,931 1,866
Convertible debentures, net of unamortized discount of $20 and $0, respectively 2,604 2,826
Derivative liability 3,187 1,785
Total current liabilities 10,005 8,746
Total liabilities 10,005 8,746
huge profits for you guys! Company has only 4K cash and 5 million CD!